Top Myeloma Research at ASH 2023 from a Patient Perspective

Thank you to our sponsors!

2

We Want to Hear From You!

Feedback Survey At the close of the meeting a feedback survey will pop up. Click “continue” to complete the survey.

This will also be emailed to you shortly after the workshop.

Please take a moment to complete this survey.

Video Replay

A replay of the webinar will be made available on our website early next week. You can find it under the Publications and Broadcasts Tab, and then under IMF Broadcasts.

A replay link will be directly emailed to all who registered for this webinar.

Top Myeloma Research Presented at ASH 2023

1

Brian G.M. Durie, MD January 4, 2023

IMF Mission ASH 2023 ➢ Total Attendance: 32,000 (28,000 in-person; 4,000 virtual) ➢ Total Number of Abstracts: 7,000 ➢ Myeloma Abstracts: over 1,000 - Oral Presentations: 136 + LBA & Plenary - Posters: About 850

6

Myeloma Support Group Leader Voices at ASH 2023 IMF Mission Read the Blogs: Myeloma Support Group Leader Voices at ASH 2023

7

Myeloma Support Group Leader Voices at ASH 2023 IMF Mission

The ASH 2023 Experience with

Michael Tuohy, Patient (In-person)

8

Jessie Daw, Patient (Virtual)

IMFMRD Mission What is the i2TEAMM?

The MRD i2TEAMM is an International Independent Team for the Endpoint Approval of MRD in Myeloma

9

IMF Mission MRD i2TEAMM Update ➢ ACTIVE engagement with FDA for 2024 ➢ Optimistic MRD at 10-5 or better will be approved AS AN EARLY ENDPOINT FOR ACCELERATED DRUG APPROVALS ➢ Full approval still requires PFS benefit ➢ REAL WORLD USE OF MRD under review

10

IMF Global Technology Platform Imaging

Iceland Early disease

Family Studies

Full sequencing

Germany

Retrospective studies

Mayo

Central Platform

France

Cure Trial

Spain

CLIA lab NGF & MASS SPEC

Immune monitoring

Pipeline trials Immune Therapy Database

7

Asian Trials Network

Blood monitoring

Centralized NGF/risk assessment

Singapore Virtual Biobank

Single cell resistance analyses Trials Pending Latin America Network

Blood DNA mutational analyses Clinical trial assessment

Australia

IMFQ&A Mission

12

IMF Mission Top ASH Abstracts

➢ 4-Drug Combos in Frontline ➢ - Daratumumab + Velcade-Revlimid-Dexamethasone (VRd)…PERSEUS Trial European Myeloma Network (EMN)… Late Breaking Abstract (LBA) - Isatuximab + Carfilzomib-Lenalidomide-Dexamethasone (KRd)…IsKia Trial (EMN 24)… Plenary

13

IMF Mission Fibrinogen and Ferritin How are Fibrinogen and Ferritin involved in ICANS and and CRS? ▪ The study concluded that higher fibrinogen and ferritin values at baseline were associated with inferior overall survival after CAR T-cell therapy.

▪ Higher baseline absolute lymphocyte counts were linked to a higher risk of ICANS and higher grade of ICANS, an important toxicity to consider for patients receiving CAR T. ▪ Higher ferritin equated to shorter progression-free survival. CAR T-cell therapy is a highly effective treatment option, but outcomes and duration of response can vary widely, so if we can use widely available tests to help determine outcomes, this could possibly impact treatment decisions.

▪ Abstract 92: Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

14

IMFNew Mission Two Key Projects

VIRTUAL TISSUE BANK

15

IMMUNE THERAPIES REGISTRY

Confidential - Not for Distribution

IMF Mission Outpatient CAR T and Bispecifics Can we safely manage CAR T and bispecifics on an Outpatient Basis?

Robin Tuohy

Care Partner and IMF Vice President – Support Groups

16

Interview with Linda Huguelet on her CAR T treatment

IMF Mission PERSEUS Trial

17

IMF Mission PERSEUS Trial

18

IMF Mission PERSEUS Trial

19

IMF Mission PERSEUS Trial

20

IMF Mission IsKia Trial

21

IMF Mission IsKia Trial

22

IMF Mission IsKia Trial

23

IMF Mission FRONTLINE 2024

❖ 4 Drugs can be approved ❖ HOWEVER …will they be reimbursed? … are added toxicity/side effects worth it?

24

IMFQ&A Mission

25

IMF Mission ASH 2023

STATUS OF MRD TESTING

26

IMF Mission ASH 2023- STATUS OF MRD TESTING

27

IMF Mission ASH 2023- STATUS OF MRD TESTING

28

IMF Mission ASH 2023- STATUS OF MRD TESTING

29

IMF Mission ASH 2023- STATUS OF MRD TESTING

30

IMFQ&A Mission

31

IMF Mission iStopMM Project

32

IMF Mission iStopMM Project

33

IMF Mission iStopMM Project

34

iStopMM Project: The Flow Chart IMFRandomization Mission

35

IMF Mission iStopMM Project

36

IMF Mission iStopMM Project

37

IMFQ&A Mission

38

Other ASH 2023 Takeaways ➢ REAL WORLD DATASETS ➢ EMPHASIS on Equity & Access and outcomes ➢ New IMMUNE THERAPIES: Biology/outcomes ➢ HR SMM: Criteria, biology, therapies ➢ AND MANY CLINICAL PEARLS

39

IMF Mission Clinical Pearls ➢ Taper DEX ➢ CAR T Access Improved/Safety Issues? ➢ Other CAR T: FasT CAR T/Dd BCMA/GPRC5D ➢ Teclistamab for HR SMM (IMMUNO Prism) vs R/KRd/Dara KRd/other ➢ Trispecifics: JNJ 5322 and HPN217 ➢ Immune therapy dose/duration questions ➢ SIDE EFFECTS: Infections/Skin, Nails, and Taste (dysgeusia) in addition to CRS/ICANS

40

IMF Mission Final Comments

FINAL COMMENTS

41

ASH 2024

42

will be held in San Diego again!

43

We Want to Hear From You!

Feedback Survey At the close of the meeting a feedback survey will pop up. Click “continue” to complete the survey.

This will also be emailed to you shortly after the workshop.

Please take a moment to complete this survey.

Video Replay

A replay of the webinar will be made available on our website early next week. You can find it under the Publications and Broadcasts Tab, and then under IMF Broadcasts.

A replay link will be directly emailed to all who registered for this webinar.

Thank you to our sponsors!

46